申请人:The Boots Company
公开号:US04772614A1
公开(公告)日:1988-09-20
Quinolones with antihypertensive activity have the general formula I, ##STR1## wherein X is the residue of an optionally substituted benzene ring; R is lower alkyl; R.sub.3 is hydrogen or lower alkyl; R.sub.1 and R.sub.2, which may be the same or different, are hydrogen, lower alkyl, or, together with the nitrogen atom to which they are attached, form a 5 to 7 membered saturated heterocyclic ring optionally containing an additional hetero atom selected from nitrogen, oxygen and sulphur and optionally substituted by 1 or more lower alkyl groups; and the dotted line between positions 2 and 3 of the quinolone nucleus represents an optional bond. The compounds are useful as antihypertensive agents. They are also indicated for use in treating heart failure and ischaemic heart disease. With the exception of the three compounds 1-methyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide, 1,N-dimethyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide and 6,7-dimethoxyl-methyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide, the quinolones of formula I are novel. Pharmaceutical compositions containing the compounds of formula I are described. Processes for preparing the novel quinolones are also described.
具有降压活性的喹诺酮化合物具有通式I,其中X是可选择取代苯环的残基;R是较低的烷基;R.sub.3是氢或较低的烷基;R.sub.1和R.sub.2可以相同也可以不同,是氢、较低的烷基或与它们所连接的氮原子一起形成一个5到7成员的饱和杂环环,该环可以选择性地包含一个额外的氮、氧或硫杂原子,并且可以选择性地被1个或多个较低的烷基基团取代;喹诺酮核的2和3位之间的虚线表示可选键。这些化合物可用作降压药物。它们还适用于治疗心力衰竭和缺血性心脏病。除了三种化合物1-甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺、1,N-二甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺和6,7-二甲氧基甲基-4-氧代-1,4-二氢喹啉-3-磺酰胺外,通式I的喹诺酮是新颖的。描述了含有通式I化合物的制药组合物。还描述了制备新颖喹诺酮的过程。